Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise
the outcomes of a cohort of patients with cancer and COVID-19 and identify potential …

Objective. Our objective was to evaluate preferences associated with grade I/II and grade III/IV
chemotherapy side effects among breast cancer patients receiving chemotherapy. We …

Subsets of breast tumors present major clinical challenges, including triple-negative,
metastatic/recurrent disease and rare histologies. Here, we developed 37 patient-derived …

Background Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M
HNSCC) progressing on platinum-based chemotherapy have poor prognoses and limited …

Methods| We prospectively assessed the treatment plan of all patients seen in the thoracic
oncology clinic at the McGill University Health Centre (MUHC) between March 2 and May 30, …

Background: The association between aromatase inhibitors and cardiovascular outcomes
among women with breast cancer is controversial. Given the discrepant findings from …

Introduction Studies suggest that patients with cancer are more likely to experience severe
outcomes from COVID-19. Therefore, cancer centres have undertaken efforts to care for …

Objectives Systemic inflammatory response and survival has not been evaluated as a
predictive factor of chemotherapy in metastatic pancreatic cancer. The aim of this study was to …

Objective To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and
glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of …

Purpose: Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline
BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). …